#vaccine research

Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.

The PreHevbrio vaccine produces higher antibody levels and offers faster protection.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

Could emotional wellbeing and good sleep promote a lasting antibody response to the COVID-19 vaccine?

Messenger RNA vaccines—also called mRNA vaccines—are some of the first COVID-19 vaccines authorized for use in the United States.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

Vaccine development is proceeding at an unprecedented pace, but could still hit snags on the way to approval.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.

A U.K. woman developed spinal inflammation after receiving an adenovirus vector vaccine.